The activity of autoimmune T cells is tightly regulated by two major types of regulatory T. cells, those that primarily express the fork-head gene FOXP3 (FOXp3+ regulatory T cells, also named T regs) , and those that do not (T regulatory-1 cells, also named Tr1). We have developed agonists that potentiate each sub-type and could be used for therapy of different autoimmune diseases.
Long ago we reported that the CXCR3 ligands CXCL10 and possibly CXCL9 potentiate effector T cells and therefore their stabilized form could be used for cancer immunotherapy. It appears that due to post transcriptional modifications (PTM) these compounds are rapidly inactivated at the tumor site. We have developed unique compounds that are resistant to these PTM that can effectively be used for cancer immunotherapy
